Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -82.14 | -1.35 | 0.04 | -0.13 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 9,373.35 | 0.00 | -27.67 | 15.36 |
| Quality | ||||
| ROIC | 0.00% | 0.01% | -2.12% | 2.50% |
| Gross Margin | 57.14% | 52.32% | 51.76% | 61.30% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -5.18% | 9.07% | 8.81% | 8.10% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -3,335.76 | 0.00 | 13.40 | -9.06 |
| Interest Coverage | 17.18 | 201.76 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.49 | 0.46 | 0.54 |
| Cash Conversion Cycle | 32,838.37 | 225.96 | 217.64 | 188.48 |